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Abstract
Insulin regulates development, metabolism, and lifespan via a conserved PI3K/Akt pathway that promotes cytoplasmic sequestration of FoxO
transcription factors. The regulation of nuclear FoxO is poorly understood. In the nematode Caenorhabditis elegans, insulin-like signaling
functions in larvae to inhibit dauer arrest and acts during adulthood to regulate lifespan. In a screen for genes that modulate C. elegans insulin-like
signaling, we identified eak-3, which encodes a novel protein that is specifically expressed in the two endocrine XXX cells. The dauer arrest
phenotype of eak-3 mutants is fully suppressed by mutations in daf-16/FoxO, which encodes the major target of C. elegans insulin-like signaling,
and daf-12, which encodes a nuclear receptor regulated by steroid hormones known as dafachronic acids. eak-3 mutation does not affect DAF-16/
FoxO subcellular localization but enhances expression of the direct DAF-16/FoxO target sod-3 in a daf-16/FoxO- and daf-12-dependent manner.
eak-3 mutants have normal lifespans, suggesting that EAK-3 decouples insulin-like regulation of development and longevity. We propose that
EAK-3 activity in the XXX cells promotes the synthesis and/or secretion of a hormone that acts in parallel to AKT-1 to inhibit the expression of
DAF-16/FoxO target genes. Similar hormonal pathways may regulate FoxO target gene expression in mammals.
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During early postembryonic development of the nematode
Caenorhabditis elegans, animals respond to unfavorable con-
ditions by arresting in an alternative larval stage called dauer.
Dauers are long-lived and equipped to withstand suboptimal
environments. Upon improvement of ambient conditions, dauers
resume larval development and progress to adulthood. The
major influence on dauer arrest is a constitutively synthesized
pheromone that induces dauer arrest and serves as an indicator of⁎ Corresponding author. Life Sciences Institute, University of Michigan, Ann
Arbor, MI 48109, USA. Fax: +1 734 615 5493.
E-mail address: pathu@umich.edu (P.J. Hu).
1 These authors contributed equally to this work.
0012-1606/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2007.12.032population density. Pheromone responses are modulated by
temperature and food availability (Riddle, 1988).
Dauer arrest is regulated by a complex signal transduction
network. In the amphid neurons, which are in direct contact
with the external environment, the DAF-11 transmembrane
guanylyl cyclase (GC) prevents dauer arrest (Birnby et al.,
2000). In a subset of these sensory neurons, DAF-11/GC
promotes the synthesis of DAF-7, a transforming growth factor-
β (TGFβ) homolog, and DAF-28, an insulin-like molecule (Li
et al., 2003; Murakami et al., 2001; Ren et al., 1996; Schackwitz
et al., 1996). DAF-7/TGFβ and DAF-28/insulin are likely
secreted and activate TGFβ receptor-like (DAF-1/TGFβRI and
DAF-4/TGFβRII) (Estevez et al., 1993; Georgi et al., 1990) and
insulin receptor-like (DAF-2/InsR) (Kimura et al., 1997)
molecules that are expressed throughout the animal. Each of
these receptors activates an evolutionarily conserved signaling
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hormonal pathway also regulates dauer arrest and is defined by
the cytochrome P450 homolog DAF-9/CYP27A1 (Gerisch et
al., 2001; Jia et al., 2002), the nuclear receptor DAF-12 (Antebi
et al., 2000), the Rieske oxygenase homolog DAF-36 (Rottiers
et al., 2006), and the Niemann–Pick C disease gene homologs
NCR-1 and NCR-2 (Sym et al., 2000).
DAF-2/InsR regulates development, metabolism, and long-
evity through a conserved PI3K/Akt/FoxO signaling pathway
(Finch and Ruvkun, 2001; Kenyon, 2005; Taniguchi et al.,
2006). Two Akt/PKB homologs, AKT-1 and AKT-2, have
distinct and overlapping functions in this pathway (Hertweck et
al., 2004; Paradis and Ruvkun, 1998). Reduction of DAF-2/
InsR signaling results in dauer arrest in replete environments
(Riddle, 1988). DAF-2/InsR pathway mutants also exhibit
increased fat storage (Ashrafi et al., 2003; Kimura et al., 1997)
and extended lifespan (Kenyon et al., 1993; Morris et al., 1996;
Paradis et al., 1999; Wolkow et al., 2002). All DAF-2/InsR
pathway mutant phenotypes require the FoxO transcription
factor DAF-16 (Ashrafi et al., 2003; Dorman et al., 1995;
Gottlieb and Ruvkun, 1994), indicating that the major target of
DAF-2/InsR signaling is DAF-16/FoxO. FoxO transcription
factors are regulated by a number of posttranslational modifi-
cations, including phosphorylation, ubiquitination, and acetyla-
tion (Barthel et al., 2005; Vogt et al., 2005). However, the bio-
logical relevance of many of these modifications remains to be
demonstrated in intact organisms, and the physiological inputs
that regulate many of these events have not been identified.
Several lines of evidence suggest that in C. elegans,
DAF-16/FoxO regulatory inputs distinct from PI3K/Akt exist.
For example, activating mutations in pdk-1 (Paradis et al.,
1999) and akt-1 (Paradis and Ruvkun, 1998) suppress dauer
arrest in age-1/PI3K mutant backgrounds more strongly than
they do in daf-2/InsR mutant backgrounds. Likewise, a weak
daf-18/PTEN loss-of-function allele suppresses dauer arrest in
age-1/PI3K mutants but not in daf-2/InsR mutants (Gil et al.,
1999; Gottlieb and Ruvkun, 1994; Inoue and Thomas, 2000;
Ogg and Ruvkun, 1998; Vowels and Thomas, 1992). Further-
more, DAF-16/FoxO that localizes to the nucleus as a con-
sequence of either loss-of-function of the 14-3-3 protein FTT-2
(Berdichevsky et al., 2006) or mutation of the consensus AKT
phosphorylation sites (Lin et al., 2001) is not fully active,
suggesting the existence of an AKT-independent mechanism of
inhibition of nuclear DAF-16/FoxO activity. Multiple genetic
screens have failed to reveal the identity of the molecules that
comprise this parallel pathway.
We now report the cloning and characterization of eak-3, a
gene encoding a novel plasma membrane-associated protein
that functions in the endocrine XXX cells. Our results define a
role for EAK-3 in the nonautonomous regulation of nuclear
DAF-16/FoxO activity.
Materials and methods
Strains
The following strains were used: N2 Bristol (wild-type), daf-2(e1370),
akt-1(mg306), eak-3(mg344), eak-4(mg348), sdf-9(ut187), eak-6(mg329),daf-16(mgDf47), daf-3(mgDf90), osm-5(p813), sqt-1(sc13) age-1(hx546),
daf-18(e1375), akt-1(mg144), daf-9(k182), daf-12(rh61rh411), daf-36(k114),
akt-2(ok393), pdk-1(sa709), ncr-1(nr2022), and ncr-2(nr2023). akt-1(mg306)
is a molecular null allele (Hu et al., 2006), and akt-1(mg144) is a gain-of-
function allele that was isolated as a suppressor of the dauer arrest phenotype
of an age-1 null allele (Paradis and Ruvkun, 1998). ncr-1(nr2022) and ncr-2
(nr2023) were provided by Dr. Weiqing Li (University of Washington, Seattle,
WA, USA), and daf-9(k182) and daf-36(k114) were provided by Dr. Adam
Antebi (Baylor College of Medicine, Houston, TX, USA). Double and triple
mutant strains were constructed using standard genetic techniques, and geno-
types were confirmed using either restriction fragment length polymorphisms
or PCR polymorphisms, with the following exceptions. The presence of the
age-1(hx546) allele was inferred based on linkage to sqt-1(sc13), and the
presence of pdk-1(sa709) in the eak-3;pdk-1 double mutant was inferred from
the strong 25 °C dauer arrest phenotype.
DAF-16∷GFP localization was assayed using strain TJ356 (zIs356) IV,
which contains a translational fusion of the DAF-16A isoform in-frame to GFP
(Henderson and Johnson, 2001). sod-3p∷GFP activity was assayed using strain
CF1553 (muIs84), which contains a transgene consisting of the sod-3 promoter
fused to a nuclear-localized GFP reporter (Libina et al., 2003).
eak-3 mutant isolation, SNP mapping, sequencing of mutant alleles,
and cDNA isolation
Isolation, mapping, and sequencing of eak-3 alleles and isolation of an eak-3
cDNAwas performed as described for eak-4, sdf-9, and eak-6 (Hu et al., 2006),
except that the 5′/3′ RACE kit was purchased from Invitrogen (Carlsbad, CA,
USA). The 5′ and 3′ ends of the longest eak-3 cDNAs identified correspond to
nucleotides 19625 and 18124, respectively, of YAC Y92C3A. We did not
identify any spliced leader sequences at the 5′ ends.
Dauer and lifespan assays
Dauer and lifespan assays were performed as previously described (Hu et al.,
2006). All dauer assays at 27 °C were performed in blinded fashion. P-values
for differences in mean lifespans were calculated using the two-sided hetero-
scedastic Student's T-test (Microsoft Excel X).
RNAi
Feeding RNAi was performed as described (Hu et al., 2006).
GFP and RFP reporter constructs
The eak-3p∷GFP promoter fusion was generated as follows: a 1203-bp
genomic DNA fragment corresponding to nucleotides 19605–20807 of YAC
Y92C3A (annotated at the National Center for Biotechnology Information,
http://www.ncbi.nlm.nih.gov/) was PCR-amplified using primers tailed with
BglII linkers. The BglII-digested PCR product was subcloned into BamHI-
digested pPD95.67 (a gift from Dr. Andrew Fire, Stanford University, Palo Alto,
CA, USA) to generate eak-3p∷GFP. Fragment orientation was confirmed by
restriction digestion. Plasmids were purified using columns from Qiagen (Venlo,
The Netherlands). The sdf-9p∷RFP construct marking the cytoplasm of the
XXX cells has been described (Hu et al., 2006). The EAK-3∷GFP translational
fusion was generated using overlap extension PCR (Hobert, 2002). A genomic
DNA fragment corresponding to nucleotides 18161–20807 of YAC Y92C3A
(encompassing the eak-3 promoter and open reading frame up to but not
including the translation termination codon) was PCR-amplified and fused to a
PCR product containing GFP and the unc-54 3′ UTR that was amplified from
pPD95.75 (also a gift from Dr. Andrew Fire). The EAK-3∷GFP G2A N-
myristoylation mutant was constructed using overlap extension PCR by
incorporating nucleotide changes resulting in mutation of glycine at residue 2
of EAK-3 to alanine. The final fusion PCR product was sequenced to confirm
the presence of the G2A mutation. Fusion PCR products were purified using the
Qiaquick PCR purification kit (Qiagen, Venlo, The Netherlands).
Transgenic animals were generated and colocalization studies performed as
described previously (Hu et al., 2006). In colocalization experiments (Figs. 4A
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and analyzed using OpenLab imaging software (Improvision, Inc., Lexington,
MA, USA). Animals harboring wild-type and G2A mutant EAK-3∷GFP (Fig.
4C), and animals harboring DAF-16∷GFP and sod-3p∷GFP reporter constructs
(Figs. 5 and S3) were visualized using an Olympus BX61 upright microscope
and analyzed using SlideBook 4.1 digital microscopy software (Intelligent
Imaging Innovations, Inc., Denver, CO, USA). Animals were mounted on 2%
agarose pads in the presence of PBS with 10 mM sodium azide, visualized, and
photographed immediately after mounting.
Real-time PCR
Synchronized wild-type and mutant animals grown at 25 °C were harvested
26 h after egg prep, and total RNAwas prepared from ∼300 to 400 animals per
strain using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH,
USA) according to the manufacturer's instructions. First-strand cDNA was
synthesized using SuperScript™ III (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer's instructions. sod-3 mRNA was quantified with SYBR®
Green-based detection using an Eppendorf realplex2 Mastercycler (Eppendorf
North America, Westbury, NY, USA) according to the manufacturer's protocol.
Forty cycles of PCR (95 °C for 15 s followed by 60 °C for one min) were
performed on cDNA template. Each sample was assayed in duplicate. sod-3
mRNA levels were normalized to act-1 mRNA levels. sod-3 primers used were
5′ TATTAAGCGCGACTTCGGTTCCCT 3′ and 5′ CGTGCTCCCAAACGT-
CAATTCCAA 3′. act-1 primers have been described (Li et al., 2007).Results
eak-3 mutants exhibit enhanced dauer arrest
In C. elegans, DAF-2/InsR signaling prevents dauer arrest,
and the degree of reduction in DAF-2/InsR signaling in any
given pathway mutant is proportional to the strength of the
dauer arrest phenotype; i.e., animals with greater reductions in
DAF-2/InsR signaling are more likely to arrest as dauers. AKT-
1 functions downstream of DAF-2/InsR and AGE-1/PI3K
(Paradis and Ruvkun, 1998) and promotes development to
adulthood by phosphorylating DAF-16/FoxO and promoting its
cytoplasmic sequestration (Hertweck et al., 2004; Lee et al.,
2001; Lin et al., 2001). akt-1(mg306) is a molecular null allele
that has a weak dauer arrest phenotype (Hu et al., 2006),
indicating that akt-1 mutation reduces but does not fully abolish
DAF-2/InsR signaling.
To identify novel genes that function in parallel to AKT-1 to
regulate dauer arrest, we performed a genetic screen for
mutants that enhance the akt-1(mg306) dauer arrest phenotype
(eak mutants). This screen, as well as three genes identified in
this screen, eak-4, sdf-9, and eak-6, has been described
elsewhere (Hu et al., 2006). The eak-3 gene is defined by
three alleles, mg331, mg335, and mg344, that complement
eak-4, sdf-9, and eak-6 mutants but do not complement each
other.
eak-3 mutants have a very weak dauer arrest phenotype at
25 °C but strongly enhance the dauer arrest phenotype of akt-
1(mg306) (Fig. 1A). eak-3;akt-1 double mutants arrest as
dauers at 25 °C to the same extent as daf-2(e1370) mutants.
The eak-3 mutant phenotype is comparable to that of eak-4,
sdf-9, and eak-6 mutants that emerged from the same genetic
screen (Hu et al., 2006). These phenotypes have been con-
firmed with a second eak-3 allele (data not shown) and areconsistent with the hypothesis that EAK-3 functions in parallel
to AKT-1. eak-3 mutants did not enhance the dauer arrest
phenotype of eak-4(mg348), sdf-9(ut187) (Fig. 1A), or eak-6
(mg329) (Fig. S1A), suggesting that EAK-3 functions in the
same pathway or complex as EAK-4, SDF-9, and EAK-6 (Hu
et al., 2006).
eak-3 mutants interact genetically with the DAF-2/InsR
pathway
Genetic analysis suggests that EAK-3 functions in the
DAF-2/InsR pathway. The 25 °C dauer arrest phenotype of
eak-3;akt-1 double mutants was suppressed by a null mutation
in daf-16/FoxO (Fig. 1B). daf-16/FoxO mutations specifi-
cally suppress phenotypes caused by DAF-2/InsR pathway
mutations (Gottlieb and Ruvkun, 1994; Vowels and Thomas,
1992). daf-16/FoxO mutation also suppressed the 27 °C dauer
arrest phenotype of eak-3 single mutants (Fig. 1C). Further-
more, daf-18/PTEN loss-of-function and akt-1 gain-of-function
mutations, which also suppress the dauer arrest phenotype of
insulin-like pathway mutations (Gil et al., 1999; Gottlieb
and Ruvkun, 1994; Ogg and Ruvkun, 1998; Paradis and
Ruvkun, 1998; Vowels and Thomas, 1992), suppressed eak-3
(mg344) dauer arrest at 27 °C (Fig. 1D). Mutations in daf-3/
SMAD (Patterson et al., 1997), which specifically suppress the
dauer arrest phenotype of daf-7/TGFβ pathway mutants
(Gottlieb and Ruvkun, 1994; Thomas et al., 1993; Vowels
and Thomas, 1992), and osm-5/Tg737 (Haycraft et al., 2001),
which specifically suppress the dauer arrest phenotype of daf-
11/GC mutants (Vowels and Thomas, 1992), did not suppress
dauer arrest in eak-3;akt-1 double mutants (Fig. 1B), suggest-
ing that EAK-3 does not impinge upon those pathways. Con-
sistent with the placement of eak-3 in the DAF-2/InsR path-
way, eak-3(mg344) enhances the weak dauer arrest phenotype
of age-1/PI3K and pdk-1 partial loss-of-function mutants
(Fig. S1B). eak-3(mg344) also enhanced dauer arrest of daf-2
(e1370) at 15 °C (Fig. S1C). eak-3(mg344) did not enhance the
dauer arrest phenotype of an akt-2 null mutant (Fig. S1B),
suggesting that EAK-3 may function in the same pathway as
AKT-2.
eak-3 mutants interact genetically with the DAF-9/CYP27A1
hormonal pathway
Since DAF-9/CYP27A1 overexpression suppresses dauer
arrest in sdf-9 mutants (Ohkura et al., 2003) and EAK-3 and
SDF-9 may function in the same pathway (Fig. 1A), we
determined whether eak-3 interacts genetically with compo-
nents of the DAF-9/CYP27A1 hormonal pathway. We were not
able to assess the effect of eak-3 mutation in a daf-9 null
background, as daf-9 null mutants undergo nonconditional
dauer arrest (Gerisch et al., 2001; Jia et al., 2002). eak-3
(mg344) did enhance dauer arrest of the partial loss-of-function
allele daf-9(k182), which has a weak dauer arrest phenotype at
25 °C (Fig. 2A) (Gerisch et al., 2001). As is the case for all
dauer-constitutive mutants, a daf-12 null mutation fully
suppressed dauer arrest in eak-3;akt-1 and eak-3(mg344)
Fig. 1. eak-3 interacts with the daf-2 insulin-like signaling pathway. Animals were assayed for dauer arrest phenotypes at 25 °C (A and B) or 27 °C (C and D). (A) eak-
3mutation enhances the dauer arrest phenotype of akt-1mutants but not of eak-4 or sdf-9mutants. (B) Dauer arrest of an eak-3;akt-1 double mutant is suppressed by a
mutation in daf-16/FoxO but not by mutations in daf-3/SMAD or osm-5/Tg737. (C) Dauer arrest of an eak-3 mutant at 27 °C is suppressed by a mutation in daf-16/
FoxO. (D) Dauer arrest of an eak-3 mutant at 27 °C is suppressed by daf-18/PTEN loss-of-function and akt-1 gain-of-function mutations. Data are represented as
mean+SD. The number of animals scored is documented in Table S1.
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dauer arrest at 25 °C (Figs. 2D and E) (Rottiers et al., 2006), and
ncr-1 and ncr-2 single mutants do not arrest as dauers at 25 °C
(Fig. S1D) (Li et al., 2004). eak-3(mg344) enhanced the dauer
arrest phenotype of a daf-36/Rieske null allele, although not to
the extent that it enhanced akt-1(mg306) dauer arrest (Fig. 2D).
eak-3(mg344) also enhanced the dauer arrest phenotype of a
ncr-1 null allele but did not enhance the dauer arrest phenotype
of a ncr-2 null allele (Fig. S1D). These results suggest that eak-
3 may act in parallel to ncr-1 and daf-36/Rieske to inhibit dauer
arrest.
The ability of eak-3(mg344) to enhance dauer arrest pheno-
types of both akt-1 and daf-36/Rieske mutants suggests that
AKT-1 and DAF-36/Rieske could conceivably act in the same
pathway. To test this possibility, we determined whether
inactivation of akt-1 by RNAi would enhance the dauer arrest
phenotype of a daf-36/Rieske loss-of-function mutant (the
proximity of akt-1 and daf-36/Rieske genes in the C. elegans
genome prevented the construction of a daf-36 akt-1 double
mutant). akt-1 RNAi enhanced dauer arrest in both eak-3 and
daf-36/Rieske mutants to a comparable extent (Fig. 2E). Sincethis daf-36/Rieske allele is a null allele (Rottiers et al., 2006),
AKT-1, EAK-3, and DAF-36/Rieske likely act in parallel
pathways.
eak-3 regulation of lifespan
DAF-2/InsR and DAF-9/CYP27A1 pathways regulate
organismal lifespan (Broue et al., 2007; Finch and Ruvkun,
2001; Gerisch et al., 2001, 2007; Jia et al., 2002; Kenyon,
2005; Rottiers et al., 2006). Since eak-3 interacts genetically
with both DAF-2/InsR and DAF-9/CYP27A1 pathways, we
assayed eak-3 mutants for lifespan phenotypes. In contrast
to daf-2(e1370), which exhibits approximately 2-fold life-
span extension compared to wild-type animals, neither eak-3
(mg344) nor eak-3;akt-1 double mutants lived longer than
wild-type animals (Figs. 3A and C, Table 1). As previously
reported (Hu et al., 2006), akt-1(mg306) animals lived slightly
longer than wild-type animals, and other eak single mutant
and eak;akt-1 double mutants had lifespans comparable to
eak-3 single and eak-3;akt-1 double mutant animals (Table 1).
Although mutation of eak genes did not significantly affect
Fig. 2. eak-3 interacts with the daf-9/CYP27A1 hormonal pathway. Animals were assayed for dauer arrest phenotypes at 25 °C (A, B, D, and E) or 27 °C (C). (A) eak-3
mutation enhances the dauer arrest phenotype of a partial loss-of-function allele of daf-9. (B) Dauer arrest of an eak-3;akt-1 double mutant is suppressed by a mutation
in daf-12. (C) Dauer arrest of an eak-3mutant at 27 °C is suppressed by a mutation in daf-12. (D) eak-3mutation enhances the dauer arrest phenotype of a daf-36 null
mutation. (E) akt-1 RNAi enhances the dauer arrest phenotype of eak-3 and daf-36 mutants. Data are represented as mean+SD. The number of animals scored is
documented in Table S1.
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slightly shorter lifespans than akt-1(mg306) single mutants
(Fig. 3A and Table 1), as did other eak;akt-1 double mutants
(Table 1).
To further investigate the role of eak-3 in lifespan regulation,
we determined the effect of eak-3 mutation on lifespan in daf-2/
InsR and daf-16/FoxO mutant backgrounds. At 20 °C, eak-3daf-2 double mutants exhibited extended longevity compared to
daf-2 single mutants (Fig. 3B). This is consistent with the
enhancement of daf-2(e1370) dauer arrest by eak-3 mutation
(Fig. S1C). eak-3 mutation did not affect the lifespan of daf-16/
FoxO mutants (Fig. 3C), suggesting that the lifespan extending
effects of eak-3 mutation in a daf-2(e1370) background (Fig.
3B) are mediated by DAF-16/FoxO.
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We used single nucleotide polymorphism mapping (Wicks et
al., 2001) to localize eak-3 to a ∼210-kb genomic interval on
the left arm of chromosome III. Rescue assays with pools ofoverlapping ∼10–12 kb PCR products (Winston et al., 2002)
that spanned the eak-3 interval indicated that eak-3 likely
corresponds to the open reading frame Y92C3A.3. Sequencing
of predicted exons and splice junctions of Y92C3A.3 in three
eak-3 alleles identified distinct point mutations in each allele
(Fig. S2). The Y92C3A.3 open reading frame lies within a large
intron of cdh-12, a cadherin gene that lies on the opposite
genomic strand. A genomic PCR fragment corresponding to this
intron and containing the predicted Y92C3A.3 promoter, open
reading frame, and 3′ untranslated region rescued the eak-3
mutant phenotype in 1 of 4 transgenic lines (data not shown).
The eak-3 promoter drives transcription specifically in the XXX
cells
To determine where eak-3 is expressed in intact animals, we
generated transgenic animals harboring a construct consisting of
the predicted eak-3 promoter fused to GFP (eak-3p∷GFP).
These animals exhibited specific GFP expression in two cells in
the head, the position and morphology of which suggested that
they were the XXX cells (Fig. 4A). Colocalization of GFP and
RFP in animals coexpressing eak-3p∷GFP and sdf-9p∷RFP,
which marks the cytoplasm of the XXX cells (Hu et al., 2006;
Ohkura et al., 2003), confirmed that the eak-3 promoter is
specifically active in the XXX cells (Fig. 4A).
An EAK-3∷GFP fusion protein localizes to the plasma
membrane of the XXX cells
We isolated eak-3 cDNAs from total C. elegans RNA and
confirmed the predicted cDNA structure (WormBase; www.
wormbase.org; Fig. S2). EAK-3 has no statistically significant
amino acid similarity to known proteins. Strikingly, 4 of the first
5 predicted amino-terminal amino acid residues are identical to
EAK-4 (Hu et al., 2006), including a glycine residue at position
2 that is invariant in N-myristoylated proteins (Maurer-Stroh et
al., 2002). However, the sixth amino acid residue, which is
conserved in most N-myristoylated proteins (Maurer-Stroh et
al., 2002), is not conserved in EAK-3.
We generated transgenic animals harboring a C-terminal
EAK-3∷GFP translational fusion construct to determine the
subcellular localization of EAK-3∷GFP. EAK-3∷GFP loca-
lized to the plasma membrane of the XXX cells. This
localization was confirmed by visualization of animals coex-
pressing EAK-3∷GFP and sdf-9p∷RFP (Fig. 4B).
To examine the role of the N-myristoylation motif in EAK-
3∷GFP plasma membrane localization, we tested the effect ofFig. 3. Effects of eak-3 mutation on lifespan. Lifespans were assayed at 25 °C
(A) or 20 °C (B and C). The number of animals scored is documented in Table
S1. Mean lifespans (days) ± standard deviation are as follows: (A; p-value vs.
wild-type): wild-type, 12.56±1.99; daf-2(e1370), 22.54±2.89 (p=4.53×
10−35); akt-1(mg306), 13.49±2.92 (p=0.06); eak-3(mg344), 11.84±2.97
(p=0.16); eak-3;akt-1, 12.64±1.79 (p=0.83). For akt-1 vs. eak-3, p=0.01;
akt-1 vs. eak-3;akt-1, p=0.08; eak-3 vs. eak-3;akt-1, p=0.11. (B) daf-2,
45.82±4.06; eak-3 daf-2, 50.85±4.58 (p=3.67×10−11). (C) Wild type,
25.47±4.61; eak-3, 24.54±5.22 (p=0.27); daf-16, 15.97±2.26; daf-16;eak-3,
16.24±2.25 (p=0.42 vs. daf-16).
Table 1
Mean lifespans of eak single and eak;akt-1 double mutants
Strain Mean±SD P vs. N2 P vs. akt-1 N
N2 12.7±2.1 – 0.002 101
daf-2(e1370) 23.5±2.7 7.5×10−79 4.8×10−68 103
akt-1(mg306) 13.7±2.6 0.002 – 105
eak-3(mg344) 12.6±2.6 0.90 0.003 105
eak-4(mg348) 12.9±1.9 0.40 0.014 97
sdf-9(ut187) 12.9±2.0 0.39 0.017 102
sdf-9(mg337) 12.9±1.9 0.39 0.014 101
eak-6(mg329) 12.9±1.6 0.42 0.008 100
eak-3;akt-1 13.0±2.1 0.29 0.029 99
eak-4;akt-1 13.1±2.2 0.19 0.058 101
akt-1 sdf-9(ut187) 12.7±2.5 0.95 0.003 99
akt-1 sdf-9(mg337) 13.0±2.5 0.40 0.033 101
eak-6;akt-1 12.8±2.1 0.77 0.005 97
Combined results from two independent experiments are shown. Lifespans from
one of these experiments have been reported previously (Hu et al., 2006).
Abbreviations: SD, standard deviation.
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for N-myristoylation on the subcellular localization of EAK-
3∷GFP. We generated transgenic animals expressing wild-typeFig. 4. Expression pattern of eak-3∷GFP fusion constructs. (A) Fluorescent protein e
(B) Fluorescent protein expression in animals harboring EAK-3∷GFP translational
wild-type EAK-3∷GFP or EAK-3∷GFP containing a mutation at the conserved glyEAK-3∷GFP and mutant EAK-3∷GFP with glycine at residue
2 mutated to alanine (G2A). Whereas wild-type EAK-3∷GFP
localizes to the plasma membrane, the G2A mutation abrogates
membrane association and results in relocalization to the
cytoplasm (Figs. 4B and C). Thus, the glycine that is absolutely
required for N-myristoylation is also required for EAK-3∷GFP
plasma membrane association. Five of six amino acids
immediately following the putative N-myristoylation motif in
EAK-3 are either lysine or arginine (residues 6–11; Fig. S2) and
may contribute to the membrane localization of EAK-3.
EAK proteins do not regulate DAF-16∷GFP subcellular
localization
Insulin-like signaling pathways inhibit FoxO transcription
factors via a conserved mechanism of Akt-mediated phosphor-
ylation and subsequent cytoplasmic sequestration (Barthel et al.,
2005; Henderson and Johnson, 2001; Lee et al., 2001; Lin et al.,
2001; Vogt et al., 2005). The suppression of eak-3 mutant
phenotypes by daf-16/FoxO mutation suggests that in wild-type
animals, EAK-3 also inhibits DAF-16/FoxO function. To deter-xpression in animals harboring eak-3p∷GFP and sdf-9p∷RFP promoter fusions.
and sdf-9p∷RFP promoter fusions. (C) GFP localization in animals expressing
cine of the N-myristoylation motif (G2A). Representative images are shown.
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cation, we examined the subcellular localization of a DAF-
16∷GFP translational fusion (Henderson and Johnson, 2001) in
wild-type, akt-1(mg306), and eak-3(mg344) mutant animals.
In wild-type animals, DAF-16∷GFP is predominantly
cytoplasmic (Fig. 5A), consistent with the presence of intact
DAF-2/InsR signaling. Mutation of akt-1 results in nuclear
translocation of DAF-16∷GFP, consistent with previous results
(Hertweck et al., 2004). In contrast, eak-3 mutation has no
effect on DAF-16∷GFP subcellular localization, indicating
that EAK-3 does not regulate the subcellular distribution of
DAF-16/FoxO.
Since sdf-9 and eak-6 likely function in the same pathway as
eak-3 (Figs. 1A and S1A), we also assayed DAF-16∷GFP
subcellular localization in sdf-9 and eak-6 mutant back-
grounds. As expected, neither sdf-9 nor eak-6 mutation affected
DAF-16∷GFP subcellular localization (Fig. S3A).
EAK proteins regulate DAF-16/FoxO target gene expression in
an akt-1 mutant background
In C. elegans, nuclear translocation of DAF-16/FoxO is not
sufficient for full DAF-16/FoxO activation (Berdichevsky et al.,
2006; Hertweck et al., 2004; Lin et al., 2001), indicating that
nuclear DAF-16/FoxO activity may be regulated independently
of Akt. We tested the ability of EAK-3 to regulate the activity of
nuclear DAF-16/FoxO by constructing wild-type and mutant
animals harboring a sod-3p∷GFP reporter construct (Libina
et al., 2003). DAF-16/FoxO directly activates transcription of
sod-3 (Oh et al., 2006), and the sod-3p∷GFP reporter serves asFig. 5. Effects of eak-3 mutation on DAF-16/FoxO subcellular localization and ac
harboring a DAF-16∷GFP translational fusion were assayed for DAF-16∷GFP subce
harboring a sod-3p∷GFP promoter fusion were assayed for GFP expression. Identic
reporter. Representative images are shown.a readout for DAF-16/FoxO activity (Libina et al., 2003). Wild-
type animals exhibited baseline expression of sod-3p∷GFP in
the head and the tail without significant GFP expression in the
intestine or body wall muscle (Fig. 5B). eak-3 mutation did not
affect sod-3p∷GFP expression significantly in a wild-type
background. Since DAF-16/FoxO remains in the cytoplasm in
eak-3 mutants (Fig. 5A), this result demonstrates that in the
absence of nuclear DAF-16/FoxO, EAK-3 does not regulate
sod-3p∷GFP transcription. akt-1 mutation increased sod-
3p∷GFP transcription above baseline in the body wall muscle.
However, intestinal sod-3p∷GFP expression remained compar-
able to that seen in wild-type animals. This indicates that in
body wall muscle, AKT-1 may be the primary regulator of
DAF-16/FoxO-mediated activation of the sod-3 promoter.
Interestingly, in the eak-3;akt-1 double mutant background,
sod-3p∷GFP expression was induced in both body wall muscle
and intestine, and intestinal GFP expression was substantially
greater in eak-3;akt-1 double mutants compared to akt-1 single
mutants (Fig. 5B). This indicates that in akt-1 mutant animals,
EAK-3 inhibits sod-3 transcription, perhaps in a tissue-specific
manner. Since the eak-3 promoter drives expression specifically
in the XXX cells (Fig. 4), EAK-3 functions nonautonomously
to inhibit nuclear DAF-16/FoxO activity in the intestine. We
observed similar sod-3p∷GFP expression patterns in sdf-9,
eak-6, akt-1 sdf-9, and eak-6;akt-1 mutants, consistent with
SDF-9, EAK-6, and EAK-3 functioning in the same pathway or
complex in the XXX cells (Fig. S3B).
We confirmed these results by examining the effects of
eak-3, eak-4, sdf-9, and eak-6 mutations on the expression of
endogenous sod-3. We isolated total RNA from wild-type andtivity in vivo. (A) Wild-type and mutant animals (late L1 to early L2 larvae)
llular localization. (B) Wild-type and mutant animals (late L1 to early L2 larvae)
al exposure times were used to photograph all animals harboring a specific GFP
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transcription PCR using gene-specific primers for sod-3.
Whereas relative endogenous sod-3 mRNA levels were
modestly increased in eak and akt-1 single mutants compared
to wild-type animals, they were dramatically elevated in all eak;
akt-1 double mutant animals compared to single mutants
(Fig. 6A). These results indicate that EAK proteins function inFig. 6. Quantification of endogenous sod-3 mRNA levels in wild-type and
mutant L2 stage animals by real-time reverse transcription PCR. (A) sod-3
mRNA levels in single and double mutants. (B) sod-3 mRNA levels in eak-3;
akt-1 double mutants after RNAi. (C) sod-3 mRNA levels after akt-1 RNAi in
wild-type, eak-3 mutant, and daf-36 mutant animals. Relative expression units
are shown. Data are represented as mean+SD.parallel to AKT-1 to inhibit DAF-16/FoxO activity on endo-
genous promoters.
In light of the observation that dauer arrest in eak-3;akt-1
double mutants requires both daf-16/FoxO (Fig. 1) and daf-12
(Fig. 2), we measured endogenous sod-3 mRNA expression
in eak-3;akt-1 double mutants after reduction of daf-16/FoxO
or daf-12 activity by RNAi. RNAi of either daf-16/FoxO or
daf-12 reduced endogenous sod-3 expression approximately
seven-fold (Fig. 6B), indicating that in eak-3;akt-1 double
mutants, DAF-12 is also required for the expression of certain
DAF-16/FoxO targets. daf-9 RNAi had no effect on sod-3
expression levels.
Since DAF-36/Rieske may function in parallel to both EAK-
3 (Fig. 2D) and AKT-1 (Fig. 2E) to inhibit dauer arrest, we
measured endogenous sod-3 mRNA levels in eak-3;daf-36
double mutants and in daf-36 single mutants after inactivating
akt-1 by RNAi. sod-3 mRNA levels were significantly in-
creased in eak-3;daf-36 double mutants compared to eak-3 and
daf-36 single mutants (Fig. 6A). akt-1 RNAi dramatically
increased sod-3 mRNA levels in both eak-3 and daf-36 mutants
(Fig. 6C). Taken together with the synthetic dauer-constitutive
phenotype of eak-3;daf-36 double mutants at 25 °C (Fig. 2D)
and the enhancement of dauer arrest in daf-36/Rieske mutants
by akt-1 RNAi (Fig. 2E), this result suggests that DAF-36
and EAK-3 act in parallel to AKT-1 and to each other to inhibit
sod-3 expression.
Discussion
EAK-3 may function in an endocrine pathway
The endocrine nature of EAK-3 function is supported by the
observation that eak-3mutation enhances a systemic phenotype,
namely dauer arrest (Figs. 1 and 2), in spite of the fact that the
eak-3 promoter is only active in the XXX cells (Fig. 4).
Furthermore, eak-3 mutation enhances DAF-16/FoxO target
gene expression nonautonomously (Fig. 5). These results are
consistent with at least two models of EAK-3 function. EAK-3
could inhibit the activity of a hormone secreted by the XXX
cells that activates nuclear DAF-16/FoxO. However, the fact
that laser ablation of the XXX cells results in a dauer-cons-
titutive phenotype suppressed by loss of daf-16/FoxO activity
in the rest of the animal (Ohkura et al., 2003) rather than a
dauer-defective phenotype suggests that the XXX cells
normally inhibit DAF-16/FoxO. This leads us to favor an
alternative model whereby EAK-3 promotes the activity of a
hormone secreted from the XXX cells that inhibits nuclear
DAF-16/FoxO activity (Fig. 7).
One plausible model of nonautonomous DAF-16/FoxO
regulation by EAK-3 invokes the secretion of insulin-like
peptide hormones that activate DAF-2/InsR on the surface of
target cells. If EAK-3 inhibits DAF-16/FoxO by promoting the
activity of a DAF-2/InsR agonist ligand, then eak-3 loss-of-
function should phenocopy daf-2 loss-of-function. However, in
contrast to the extended lifespan exhibited by sixteen
independent daf-2 loss-of-function alleles (Gems et al., 1998),
eak-3 loss-of-function mutants have normal lifespans (Fig. 3
Fig. 7. Model of EAK-3 regulation of DAF-16/FoxO target gene expression in (A) wild-type and (B) eak-3;akt-1 double mutant animals. Schematics of an XXX cell
(top of figure) and a target cell (bottom of figure) are shown. Dashed arrows and lines denote hypothesized relationships between molecules. See text for details.
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promotes DAF-16∷GFP nuclear localization (Henderson and
Johnson, 2001; Lee et al., 2001; Lin et al., 2001), eak-3 loss-of-
function mutation has no effect on DAF-16∷GFP subcellular
distribution (Fig. 5A). These observations suggest that EAK-3
does not regulate the synthesis or secretion of DAF-2/InsR
ligands.
Genetic interactions of eak-3 with the DAF-9/CYP27A1
hormonal pathway (Figs. 2 and S1D) suggest that EAK-3 may
regulate the synthesis and/or secretion of a steroid hormone.
Similar interactions have been described for sdf-9, a gene that is
also specifically expressed in the XXX cells (Hu et al., 2006;
Ohkura et al., 2003) and that also emerged from our genetic
screen (Hu et al., 2006). Intriguingly, daf-9/CYP27A1 is ex-
pressed in the XXX cells (Ohkura et al., 2003) as well as in
other tissues (Gerisch et al., 2001; Jia et al., 2002). Over-
expression of daf-9/CYP27A1 can rescue the sdf-9 mutant
phenotype (Ohkura et al., 2003), suggesting that DAF-9/
CYP27A1 functions either parallel to or downstream of SDF-9.
The lack of phenotypic enhancement in an eak-3;sdf-9 double
mutant (Fig. 1A) and the colocalization of EAK-3 and SDF-9 in
the XXX cells (Fig. 4) suggest that DAF-9/CYP27A1 may also
function parallel to or downstream of EAK-3. These results
would be consistent with EAK-3 and SDF-9 functioning in the
XXX cells to promote the DAF-9/CYP27A1-dependent synth-
esis of a steroid hormone that inhibits DAF-16/FoxO activity in
target tissues. In this scenario, DAF-9/CYP27A1 expressed in
the XXX cells would be predicted to have a function upstream
of DAF-16/FoxO. The observation that daf-16/FoxO mutations
do not suppress the dauer arrest phenotype of daf-9/CYP27A1
mutants (Gerisch et al., 2001; Jia et al., 2002) suggests thatDAF-9/CYP27A1 also functions in parallel to or downstream of
DAF-16/FoxO in other tissues.
eak-3 and sdf-9 mutations enhance dauer arrest in ncr-1
mutants but do not influence dauer arrest in ncr-2 mutants (Fig.
S1D) (Ohkura et al., 2003). The observation that the ncr-2
promoter is only active in the XXX cells during early larval
stages (Li et al., 2004) suggests that eak-3 and sdf-9 mutations
may fail to enhance dauer arrest in ncr-2 mutants by virtue of
EAK-3 and SDF-9 acting in the same pathway as NCR-2 in the
XXX cells. Alternatively, this may be a consequence of the
stronger phenotype of ncr-1mutants compared to ncr-2mutants
(Li et al., 2004). It is not known whether the difference in ncr-1
and ncr-2 mutant phenotypes is a consequence of the distinct
expression patterns of ncr-1 and ncr-2 or of intrinsic differences
in the function of NCR-1 and NCR-2 proteins.
EAK-3 decouples DAF-16/FoxO regulation of dauer arrest and
lifespan
The physiological consequences of DAF-16/FoxO activation
are determined at least in part by where in the animal and when
during its life history DAF-2/InsR signaling is inhibited. For
example, DAF-16/FoxO activity in neurons has dispropor-
tionate effects on dauer arrest compared to lifespan, whereas
intestinal DAF-16/FoxO activity affects lifespan more promi-
nently than dauer arrest (Libina et al., 2003). Also, transient
activation of DAF-16/FoxO during early larval development
promotes dauer arrest without impacting organismal lifespan,
whereas DAF-16/FoxO activation during early adulthood pro-
motes extended longevity (Dillin et al., 2002). Although some
proteins have been implicated in the regulation of lifespan-
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Wolff et al., 2006), to our knowledge, EAK-3 is the first protein
described that primarily regulates DAF-16/FoxO dauer-indu-
cing activity. The ability of eak-3 mutation to extend the
lifespan of daf-2(e1370)mutants at 20 °C (Fig. 3B) is consistent
with its enhancement of dauer arrest in daf-2(e1370) mutants at
low temperatures (Fig. S1C) and suggests that EAK-3 can
regulate lifespan in certain contexts.
The mechanisms underlying EAK-3 decoupling of the dauer
arrest and lifespan regulatory functions of DAF-16/FoxO remain
obscure. The eak-3 promoter is active from late embryogenesis
through young adulthood (data not shown), suggesting that eak-
3 expression is not limited to the developmental stages during
which the dauer arrest decision is made. Furthermore, although
intestinal DAF-16/FoxO activity correlates with lifespan exten-
sion (Libina et al., 2003), eak-3;akt-1 mutants also exhibit
increased intestinal DAF-16/FoxO activity during late larval
stages (data not shown) but do not have extended longevity (Fig.
3A and Table 1). This suggests that activation of intestinal DAF-
16/FoxO per se is not sufficient to extend organismal lifespan.
EAK-3 regulates DAF-16/FoxO activity
Since daf-16/FoxO loss-of-function fully suppresses eak-3
dauer arrest phenotypes (Fig. 1), DAF-16/FoxO is a major
genetic target of EAK-3. This is consistent with the observation
that loss-of-function mutations in daf-18/PTEN and gain-of-
function mutations in akt-1 also suppress eak-3 mutant phe-
notypes (Fig. 1D). The design of the genetic screen from which
eak-3 was isolated (Hu et al., 2006), and the regulatory effects
of EAK-3 on DAF-16/FoxO activity (Figs. 5B and 6) suggest
that EAK-3 functions in parallel to AKT-1 to inhibit DAF-16/
FoxO activity.
In contrast to its interactions with akt-1 mutants, eak-3
mutation did not enhance dauer arrest in an akt-2 mutant
background (Fig. S1B). This could be secondary to the weaker
phenotypic effects of akt-2 loss-of-function compared to akt-1
loss-of-function (Hertweck et al., 2004; Paradis and Ruvkun,
1998; Quevedo et al., 2007). Alternatively, EAK-3 may inhibit
DAF-16/FoxO by activating AKT-2. This would not be incon-
sistent with the lack of effect of eak-3 mutation on DAF-
16∷GFP subcellular distribution (Fig. 5A), as AKT-2 does not
strongly influence DAF-16∷GFP localization (Hertweck et al.,
2004). Reporters driven by akt-1 and akt-2 promoters are both
widely expressed (Paradis and Ruvkun, 1998), suggesting that
differences in spatial expression patterns do not account for the
differential phenotypic effects of eak-3 mutation in akt-1 and
akt-2 mutant backgrounds.
Mechanisms of DAF-16/FoxO regulation
Most proteins known to regulate DAF-16/FoxO do so by
controlling its subcellular distribution. For example, the kinases
JNK-1 (Oh et al., 2005) and CST-1 (Lehtinen et al., 2006) and
the intestinal protein KRI-1 (Berman and Kenyon, 2006) pro-
mote DAF-16/FoxO nuclear translocation. Conversely, AKT-1
(Hertweck et al., 2004) and the 14-3-3 proteins PAR-5(Berdichevsky et al., 2006) and FTT-2 (Berdichevsky et al.,
2006; Li et al., 2007) promote the cytoplasmic sequestration of
DAF-16/FoxO. Intriguingly, although FTT-2 inhibits DAF-16/
FoxO nuclear localization, it appears to be required for SIR-2.1-
dependent activation of nuclear DAF-16/FoxO (Berdichevsky
et al., 2006; Wang et al., 2006).
Two proteins, SMK-1 (Wolff et al., 2006) and SIR-2.1
(Berdichevsky et al., 2006), have been shown to potentiate
DAF-16/FoxO activity without affecting DAF-16/FoxO sub-
cellular localization; interestingly, both regulate DAF-16/FoxO-
dependent lifespan extension without strongly impacting DAF-
16/FoxO-mediated dauer arrest (Tissenbaum and Guarente,
2001; Wolff et al., 2006). It is conceivable that EAK-3 prevents
dauer arrest by inhibiting molecules that function analogously
to SMK-1 and SIR-2.1 in dauer regulation.
DAF-12 may regulate a subset of DAF-16/FoxO target genes
We have shown that DAF-12 is required for maximal
endogenous sod-3 expression in eak-3;akt-1 double mutants
(Fig. 6B). DAF-12 is also required for full expression of
intestinal sod-3∷GFP in eak-3;akt-1 double mutants (data not
shown). To our knowledge, this is the first demonstration that
DAF-12 is required for the expression of a specific DAF-16/
FoxO target gene. The requirement of DAF-12 for the dauer
arrest and sod-3 expression phenotypes of eak-3 mutants (Figs.
2 and 6B) raises the possibility that EAK-3 may regulate DAF-
16/FoxO target gene expression indirectly via DAF-12. For
example, nuclear DAF-16/FoxO and unliganded DAF-12 could
act in parallel to activate intestinal sod-3 expression by con-
verging on the sod-3 promoter. sod-3 expression would be
inhibited by activation of either AKT-1 (resulting in DAF-16/
FoxO phosphorylation and cytoplasmic sequestration) or EAK-
3 (resulting in dafachronic acid synthesis and binding to DAF-
12). daf-12 RNAi had no effect on DAF-16∷GFP nuclear
localization in wild-type, akt-1mutant, or eak-3mutant animals,
and daf-9 RNAi did not affect DAF-16∷GFP localization in
wild-type or akt-1 mutants and resulted in DAF-16∷GFP
nuclear localization in less than 10% of eak-3 mutants (data not
shown), suggesting that the major regulatory effect of the
hormonal pathway on DAF-16/FoxO target gene expression
does not occur via changes in DAF-16/FoxO subcellular
distribution.
This model also accommodates the observation that
DAF-36/Rieske may act in parallel to both AKT-1 and EAK-
3 (Figs. 2D, 2E, 6A, and 6C), as DAF-36/Rieske is thought to
participate in the biosynthesis of dafachronic acids (Rottiers
et al., 2006). Although both EAK-3 and DAF-36/Rieske may
act in dafachronic acid biosynthetic pathways, they may
function in parallel by virtue of their expression in distinct
cells; expression of daf-36 in the XXX cells has not been
observed (Rottiers et al., 2006).
A model for EAK-3 function
Based on our data as well as previously published work,
we propose a model for EAK-3 function (Fig. 7). In the
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(Hu et al., 2006) to promote the synthesis and/or secretion of
a hormone that regulates the expression of DAF-16/FoxO
target genes nonautonomously. XXX-specific expression of
akt-1 rescues the dauer arrest phenotype of an eak-4;akt-1
double mutant (Hu et al., 2006), suggesting that AKT-1 func-
tions in the XXX cells to prevent dauer arrest. AKT-1 may
target a protein distinct from DAF-16/FoxO in the XXX cells,
since the major isoform of DAF-16/FoxO that regulates dauer
arrest is not expressed at detectable levels in the XXX cells
(Hu et al., 2006). In the XXX cells, EAK-3, other EAK pro-
teins, and AKT-1 may regulate one or more proteins in-
volved in hormone synthesis and/or secretion, such as DAF-9/
CYP27A1 or other undiscovered proteins (indicated by the
orange shape).
In target cells, AKT-1 functions to promote DAF-16/FoxO
cytoplasmic sequestration, and the steroid hormone (or hor-
mones) produced in the XXX cells acts in parallel to AKT-1 to
inhibit the transcription of DAF-16/FoxO target genes, possibly
via DAF-12. In wild-type animals, DAF-16/FoxO is seques-
tered in the cytoplasm, and DAF-12 is bound to steroid
hormone ligands (Fig. 7A). When akt-1 is mutated, DAF-16/
FoxO translocates to the nucleus; however, certain DAF-16/
FoxO target genes such as sod-3 are not fully induced in the
presence of liganded DAF-12. In eak-3;akt-1 double mutants,
nuclear DAF-16/FoxO and unliganded DAF-12 cooperate to
promote dauer arrest by regulating the expression of a subset of
DAF-16/FoxO target genes (Fig. 7B). This model does not
exclude the possibility that EAK-3 may also inhibit the ex-
pression of DAF-16/FoxO target genes through DAF-12-
independent mechanisms.
It is noteworthy that the genetic screen that yielded
eak-3 also identified three other genes that remain to be
characterized. These genes could encode components of the
hormone biosynthetic or regulatory machinery in the XXX
cells as well as mediators of hormonal effects in target
tissues. Their molecular identities and functions will illu-
minate the EAK-3 endocrine pathway and may also shed
light on how FoxO transcription factors are regulated in
mammals.
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